Cell and Gene Therapy Today—May 7, 2026

LucidQuest

5 hours ago

This week’s Gene and Cell Therapy update highlights regulatory momentum, clinical progress, manufacturing readiness, financing, and platform expansion.

In Today’s Newsletter

Dive deeper

🧬 Viralgen and Elaaj Bio advance ELJ-101 for CDKL5 Deficiency Disorder [1] [Spain–UK • 05 May 2026]

https://www.prnewswire.com/news-releases/viralgen-partners-with-elaaj-bio-to-advance-gene-therapy-program-for-cdkl5-deciency-disorder-302761283.html
Context: Viralgen will support Elaaj Bio and the Loulou Foundation with AAV process development, scale-up, analytics, and quality control.
Key point: The companies are advancing ELJ-101, an investigational CDKL5 gene therapy, toward a first clinical trial planned for early 2027.
Implication: Signals pipeline investment and modality expansion.

✂️ CRISPR Therapeutics posts Q1 update across CASGEVY and pipeline programs [2] [Global • 04 May 2026]

https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-first-7
Context: CASGEVY is approved across multiple regions for eligible patients aged 12 years and older with severe SCD or TDT.
Key point: CRISPR reported $43 million in Q1 2026 CASGEVY revenue, over 500 global treatment journeys initiated, and US pediatric submission progress.
Implication: May influence prescriber choice and payer reviews pending full data.

🧠 uniQure advances AMT-130 while ending AMT-162 development [3] [US–UK • 05 May 2026]

https://www.globenewswire.com/news-release/2026/05/05/3287519/0/en/uniqure-announces-first-quarter-2026-financial-results-and-provides-recent-company-updates.html
Context: uniQure is pursuing AMT-130 for Huntington’s disease, AMT-260 for MTLE, AMT-191 for Fabry disease, and had studied AMT-162 in SOD1-ALS.
Key point: The company has a Type B FDA meeting planned for AMT-130 and expects a UK MAA submission in Q3 2026, while discontinuing AMT-162.
Implication: May influence prescriber choice and payer reviews pending full data.

💸 Latus Bio raises $97 million for scalable AAV gene therapies [4] [US • 04 May 2026]

https://www.businesswire.com/news/home/20260504989731/en/Latus-Bio-Announces-%2497-Million-Series-A-Financing-to-Expand-the-Reach-of-Gene-Therapy-to-Larger-Populations
Context: Latus Bio is developing engineered AAV capsids for CNS and broader indications, including LTS-201 and LTS-101.
Key point: The company closed a $97 million Series A to fund LTS-201 toward an IND in Q3 2026 and LTS-101 toward initial data by year-end.
Implication: Signals pipeline investment and modality expansion.

🧪 Apertura and TSC Alliance collaborate on TSC gene therapy programs [5] [US • 05 May 2026]

https://www.prnewswire.com/news-releases/apertura-gene-therapy-and-the-tsc-alliance-announce-collaboration-to-advance-gene-therapy-programs-designed-to-treat-tuberous-sclerosis-complex-tsc-302762125.html
Context: TSC is a rare genetic disease with major neurological burden, including seizures and refractory epilepsy in many patients.
Key point: Apertura and the TSC Alliance will use Apertura’s intravenously delivered TfR1 CapX AAV capsid to advance TSC gene therapy programs.
Implication: Signals pipeline investment and modality expansion.

👁️ Atsena reports six-month LIGHTHOUSE data for ATSN-201 in XLRS [6] [US–EU • 04 May 2026]

https://www.globenewswire.com/news-release/2026/05/04/3286637/0/en/Atsena-Presents-Positive-Interim-Six-Month-Results-from-Part-B-of-Phase-1-2-3-LIGHTHOUSE-Trial-Evaluating-ATSN-201-in-Patients-with-X-linked-Retinoschisis.html
Context: Part B of LIGHTHOUSE evaluated adults and pediatric patients with XLRS; pivotal Part C is enrolling 76 patients in North America and Europe.
Key point: Atsena reported six-month structural and functional improvements in treated adults and favorable safety, with BLA filing targeted for 2028.
Implication: May influence prescriber choice and payer reviews pending full data.

🏭 Fate’s FT819 selected for FDA CDRP manufacturing readiness program [7] [US • 05 May 2026]

https://www.globenewswire.com/news-release/2026/05/05/3287697/24675/en/fate-therapeutics-selected-for-u-s-fda-chemistry-manufacturing-and-controls-development-and-readiness-pilot-program-to-support-manufacturing-readiness-of-ft819.html
Context: FT819 is an off-the-shelf anti-CD19 CAR T-cell therapy candidate made from an engineered clonal iPSC master line.
Key point: FDA selected FT819 for the CDRP program to support CMC readiness for moderate-to-severe SLE, alongside existing RMAT designation.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 Valerio launches InVimmune for in vivo cell therapy [8] [04 May 2026]

https://www.pharmiweb.com/press-release/2026-05-04/valerio-therapeutics-announces-the-launch-of-invimmune-a-new-company-dedicated-to-developing-differ
Context: InVimmune will use Valerio’s single-domain antibody platform and targeted-delivery capabilities for immune reprogramming.
Key point: Valerio launched InVimmune to develop in vivo cell therapy approaches, with an initial oncology focus.
Implication: Signals pipeline investment and modality expansion.

🇯🇵 GC Cell wins Japanese CPC certification for cell therapy manufacturing [9] [Japan–South Korea • 06 May 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=31531
Context: Japan’s CPC certification validates regenerative medicine and cell therapy manufacturing facilities and quality systems.
Key point: GC Cell received MHLW certification for its Cell Processing Center after PMDA inspection, supporting supply of Immuncell-LC and CD5 CAR-NK work in Japan.
Implication: Introduces competition that may affect pricing and formulary access.

Why It Matters

Gene therapy financing and collaborations are clustering around CNS and rare disease programs, including CDKL5 Deficiency Disorder, Huntington’s disease, TSC, CLN2 disease, and XLRS. [1][4][5][6]
Manufacturing readiness remains a central bottleneck, reflected in Viralgen’s AAV scale-up role, Fate’s FDA CDRP selection, and GC Cell’s Japanese CPC certification. [1][7][9]
Regulatory strategy is becoming more region-specific, with CRISPR, uniQure, Atsena, Fate, and GC Cell highlighting US, UK, EU, Japan, and access pathways. [2][3][6][7][9]
Cell therapy platforms are moving beyond oncology into autoimmune disease, while in vivo and off-the-shelf approaches aim to reduce delivery and access constraints. [2][7][8]

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 See the full Cell and Gene Therapy archive on our research hub page.

FAQ

What is ELJ-101, and who is developing it?

ELJ-101 is an investigational CDKL5 gene therapy being advanced by Elaaj Bio, with Viralgen supporting AAV manufacturing development and scale-up. A first clinical trial is planned for early 2027. [1]

What did CRISPR Therapeutics report about CASGEVY?

CRISPR Therapeutics reported $43 million in Q1 2026 CASGEVY revenue and more than 500 people globally initiating the treatment journey. Vertex also completed a US pediatric submission for ages 5–11. [2]

What is the status of uniQure’s AMT-130 for Huntington’s disease?

uniQure plans a Type B FDA meeting to discuss trial design and statistical plans, and expects to submit a UK MAA in Q3 2026 based on three-year data. [3]

What will Latus Bio use the $97 million Series A for?

Latus Bio said proceeds will fund operations through milestones for LTS-201 in Huntington’s disease and LTS-101 in CLN2 disease, plus additional preclinical AAV programs. [4]

What did Atsena report for ATSN-201 in X-linked retinoschisis?

Atsena reported interim six-month Part B data showing structural and functional improvements in treated adults and a favorable safety profile. Pivotal Part C enrollment is underway. [6]

Why is Fate Therapeutics’ CDRP selection important for FT819?

The FDA CDRP program gives FT819 added CMC-focused engagement to support manufacturing readiness as Fate advances a potentially registrational Phase 2 study in SLE. [7]

Entities / Keywords

Viralgen, Elaaj Bio, Loulou Foundation, ELJ-101, CDKL5 Deficiency Disorder, CDD, AAV, rAAV
CRISPR Therapeutics, CASGEVY, exagamglogene autotemcel, SCD, TDT, CTX310, CTX460, CTX340, CTX321, CTX611, zugo-cel, CTX213
uniQure, AMT-130, Huntington’s disease, AMT-260, mesial temporal lobe epilepsy, MTLE, AMT-191, Fabry disease, AMT-162, SOD1-ALS, HEMGENIX
Latus Bio, LTS-201, LTS-101, Huntington’s disease, CLN2 disease, engineered AAV capsids
Apertura Gene Therapy, TSC Alliance, tuberous sclerosis complex, TSC, TfR1 CapX, transferrin receptor 1
Atsena Therapeutics, ATSN-201, LIGHTHOUSE, X-linked retinoschisis, XLRS, microperimetry, BLA
Fate Therapeutics, FT819, iPSC-derived CAR T, anti-CD19 CAR T, SLE, lupus nephritis, RMAT, CDRP
Valerio Therapeutics, InVimmune, in vivo cell therapy, single-domain antibody platform, immune reprogramming
GC Cell, Cell Processing Center, CPC, MHLW, PMDA, Immuncell-LC Injection, CD5 CAR-NK